Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M. Pratz KW, et al. Among authors: bixby d. Haematologica. 2023 Mar 1;108(3):705-716. doi: 10.3324/haematol.2022.281216. Haematologica. 2023. PMID: 36226495 Free PMC article. Clinical Trial.
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC. Swords RT, et al. Br J Haematol. 2015 May;169(4):534-43. doi: 10.1111/bjh.13323. Epub 2015 Mar 2. Br J Haematol. 2015. PMID: 25733005 Free article. Clinical Trial.
Minimizing waste during preparation of blinatumomab infusions.
Marini BL, Wechter AR, Burke PW, Bixby D, Perissinotti AJ. Marini BL, et al. Among authors: bixby d. Am J Health Syst Pharm. 2016 Jan 15;73(2):19-20. doi: 10.2146/ajhp150420. Am J Health Syst Pharm. 2016. PMID: 26721530 No abstract available.
Catalyzing improvements in ALL therapy with asparaginase.
Marini BL, Perissinotti AJ, Bixby DL, Brown J, Burke PW. Marini BL, et al. Blood Rev. 2017 Sep;31(5):328-338. doi: 10.1016/j.blre.2017.06.002. Epub 2017 Jul 5. Blood Rev. 2017. PMID: 28697948 Review.
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia.
Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS. Stein EM, et al. Among authors: bixby d. Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1. Blood. 2018. PMID: 29196412 Free PMC article. Clinical Trial.
100 results